Day: February 24, 2022

ROUYN-NORANDA, Québec, Feb. 24, 2022 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to inform shareholders that three of the largest data analytical firms have positively evaluated Globex. The firms listed have published the indicated comments reported below on the dates marked summarizing in part extensive analysis now available from many brokerage firms which pay for such analysis.Data Analyst Firm Report Date Principal CommentsMorningstar Inc. February 23, 2022 $2.69 (Fair Value Estimate) “Globex is valued at a 51% discount.”CFRA February 18, 2022 Strong Buy, “Globex’s overall score...

Preliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity FLORHAM PARK, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) —  PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology, today announced the presentation of preliminary safety data. The data are based on a total of 18 checkpoint inhibitor (CPI) naïve patients from the Company’s ongoing VERSATILE-002 Phase 2 study. The study is being conducted in collaboration with Merck (known...

RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) — North Carolina-headquartered First Citizens Bank continues to be recognized as a leader in small business and middle market banking, receiving a total of 22 Greenwich Excellence and Brand Awards for 2021. “These awards place First Citizens among the top tier of business banks in the nation and are a testament to the quality and depth of services we provide our customers,” said Patrick Noble, business services executive for First Citizens Bank. “For 124 years we’ve worked alongside our business clients, building strong, mutual relationships and helping them grow and manage their money. These honors signify the great confidence they place in us, and we’re extremely proud to be recognized by those we serve.” First Citizens garnered 22 awards —17 wins in the Small Business Banking category...

Shareholders can now exchange blocks of 20 shares of common stock into a tradable $25 perpetual, convertible preferred stock with a 6% annual dividend Offering price represents a 127% premium to the closing share price of $0.55 on January 25, 2022, the day prior to the commencement of the original Offer Shares tendered will be retired, reducing share count by approximately 30% Participating shareholders should instruct their broker to tender their shares well before the expiration time of 11:59 p.m. EST on March 10, 2022, to give their broker enough time to tender their sharesIRVING, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ: XELA) announced today that it has amended the previously announced offer (the “Offer”) to exchange up to 100,000,000 shares of its Common Stock...

Media Release COPENHAGEN, Denmark, and BOTHELL, Wash., February 24, 2022Data from the innovaTV 207 global phase 2 trial to be presented at the American Society for Radiation Oncology (ASTRO) 2022 Multidisciplinary Head and Neck Cancers SymposiumGenmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) will present preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (TIVDAK®) as a monotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN) who experienced disease progression on or after a first-line platinum-containing regimen and a checkpoint inhibitor. Early results showed tisotumab vedotin demonstrated a manageable safety profile and promising preliminary antitumor activity in this patient population with the primary endpoint of confirmed objective response...

NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced its unaudited and preliminary results for 2021. The Company anticipates posting revenues of $8.9 million, an increase of $2.8 million from 2020, representing a 45% year-over-year increase. Additionally, preliminary Q4-2021 revenues of $2.4 million represent a 25% increase from revenues of $1.9 million in Q4-2020. The Company shows positive revenues for 2021 even with the challenge of access to physician offices and patients deferring non-emergency office visits related to COVID protocols. The main increase in revenue growth in 2021 came from Pathology Diagnostic Testing. We anticipate continued growth in 2022 as lifting of COVID related restrictions allow the practice of medicine to return to normal. Diagnostic...

VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) — Apollo Silver Corp. (TSX.V:APGO, OTCQB:APGOF, FSE:6ZF0) (“Apollo” or the “Company”) is pleased to announce that a video recording of its webinar from last Wednesday, February 16, 2022 at 1:00 p.m. PST, is now live on its website. The webinar was hosted by Tom Peregoodoff, President and CEO, and Cathy Fitzgerald, VP Exploration and Resource Development, who reviewed the Company’s Maiden National Instrument (“NI”) 43-101 Mineral Resource Estimates for the Waterloo and Langtry silver properties, now collectively referred to as the Calico Silver Project (“Calico” or the “Calico Project”), located in San Bernardino County, California, as disclosed in the Company’s news release dated February 9, 2022. In addition to reviewing the mineral resource estimate results, Tom and...